Optimisation  ||| S:0 E:13 ||| NNP
of  ||| S:13 E:16 ||| IN
replication-selective  ||| S:16 E:38 ||| JJ
oncolytic  ||| S:38 E:48 ||| JJ
adenoviral  ||| S:48 E:59 ||| JJ
mutants  ||| S:59 E:67 ||| NN
in  ||| S:67 E:70 ||| IN
combination  ||| S:70 E:82 ||| NN
with  ||| S:82 E:87 ||| IN
chemotherapeutics  ||| S:87 E:105 ||| JJ
Replication-selective  ||| S:105 E:127 ||| JJ
oncolytic  ||| S:127 E:137 ||| JJ
adenoviruses  ||| S:137 E:150 ||| NNS
are  ||| S:150 E:154 ||| VBP
promising  ||| S:154 E:164 ||| VBG
anti-tumour  ||| S:164 E:176 ||| JJ
therapeutic  ||| S:176 E:188 ||| JJ
agents  ||| S:188 E:195 ||| NNS
that  ||| S:195 E:200 ||| WDT
have  ||| S:200 E:205 ||| VBP
been  ||| S:205 E:210 ||| VBN
proven  ||| S:210 E:217 ||| VBN
safe  ||| S:217 E:222 ||| JJ
in  ||| S:222 E:225 ||| IN
hundreds  ||| S:225 E:234 ||| NNS
of  ||| S:234 E:237 ||| IN
patients ||| S:237 E:245 ||| NNS
.  ||| S:245 E:247 ||| .
While  ||| S:247 E:253 ||| IN
clinical  ||| S:253 E:262 ||| JJ
efficacy  ||| S:262 E:271 ||| NN
was  ||| S:271 E:275 ||| VBD
limited  ||| S:275 E:283 ||| VBN
with  ||| S:283 E:288 ||| IN
the  ||| S:288 E:292 ||| DT
viral  ||| S:292 E:298 ||| JJ
mutants  ||| S:298 E:306 ||| NNS
alone ||| S:306 E:311 ||| RB
,  ||| S:311 E:313 ||| ,
outcomes  ||| S:313 E:322 ||| NNS
were  ||| S:322 E:327 ||| VBD
improved  ||| S:327 E:336 ||| VBN
in  ||| S:336 E:339 ||| IN
combination  ||| S:339 E:351 ||| NN
with  ||| S:351 E:356 ||| IN
chemotherapeutics ||| S:356 E:373 ||| NN
.  ||| S:373 E:375 ||| .
To  ||| S:375 E:378 ||| TO
further  ||| S:378 E:386 ||| JJ
increase  ||| S:386 E:395 ||| NN
efficacy  ||| S:395 E:404 ||| NN
of  ||| S:404 E:407 ||| IN
viral-based  ||| S:407 E:419 ||| JJ
therapies  ||| S:419 E:429 ||| NNS
it  ||| S:429 E:432 ||| PRP
is  ||| S:432 E:435 ||| VBZ
necessary  ||| S:435 E:445 ||| JJ
to  ||| S:445 E:448 ||| TO
explore  ||| S:448 E:456 ||| VB
the  ||| S:456 E:460 ||| DT
cellular  ||| S:460 E:469 ||| JJ
mechanisms  ||| S:469 E:480 ||| NNS
responsible  ||| S:480 E:492 ||| JJ
for  ||| S:492 E:496 ||| IN
enhanced  ||| S:496 E:505 ||| JJ
tumour  ||| S:505 E:512 ||| JJ
elimination  ||| S:512 E:524 ||| NN
in  ||| S:524 E:527 ||| IN
combination  ||| S:527 E:539 ||| NN
with  ||| S:539 E:544 ||| IN
cytotoxic  ||| S:544 E:554 ||| JJ
drugs  ||| S:554 E:560 ||| NNS
and  ||| S:560 E:564 ||| CC
to  ||| S:564 E:567 ||| TO
develop  ||| S:567 E:575 ||| VB
mutants  ||| S:575 E:583 ||| VBN
with  ||| S:583 E:588 ||| IN
higher  ||| S:588 E:595 ||| JJR
potency ||| S:595 E:602 ||| NN
.  ||| S:602 E:604 ||| .
To  ||| S:604 E:607 ||| TO
this  ||| S:607 E:612 ||| DT
end  ||| S:612 E:616 ||| NN
we  ||| S:616 E:619 ||| PRP
generated  ||| S:619 E:629 ||| VBD
a  ||| S:629 E:631 ||| DT
set  ||| S:631 E:635 ||| NN
of  ||| S:635 E:638 ||| IN
novel  ||| S:638 E:644 ||| NN
adenoviral  ||| S:644 E:655 ||| NN
mutants  ||| S:655 E:663 ||| NN
with  ||| S:663 E:668 ||| IN
deletions  ||| S:668 E:678 ||| NNS
of  ||| S:678 E:681 ||| IN
the  ||| S:681 E:685 ||| DT
anti-apoptotic  ||| S:685 E:700 ||| JJ
E1B19K-gene  ||| S:700 E:712 ||| NN
and  ||| S:712 E:716 ||| CC
the  ||| S:716 E:720 ||| DT
pRb-binding  ||| S:720 E:732 ||| JJ
E1ACR2-region ||| S:732 E:745 ||| NN
.  ||| S:745 E:747 ||| .
Mutants  ||| S:747 E:755 ||| NNP
with  ||| S:755 E:760 ||| IN
the  ||| S:760 E:764 ||| DT
E1B19K  ||| S:764 E:771 ||| NNP
deletion  ||| S:771 E:780 ||| VBD
significantly  ||| S:780 E:794 ||| RB
increased  ||| S:794 E:804 ||| VBN
tumour  ||| S:804 E:811 ||| JJ
cell  ||| S:811 E:816 ||| NN
killing  ||| S:816 E:824 ||| VBG
in  ||| S:824 E:827 ||| IN
combination  ||| S:827 E:839 ||| NN
with  ||| S:839 E:844 ||| IN
cytotoxic  ||| S:844 E:854 ||| JJ
drugs  ||| S:854 E:860 ||| NNS
including  ||| S:860 E:870 ||| VBG
gemcitabine ||| S:870 E:881 ||| NN
,  ||| S:881 E:883 ||| ,
5-fluorouracil  ||| S:883 E:898 ||| NN
( ||| S:898 E:899 ||| -LRB-
5-FU ||| S:899 E:903 ||| NNP
) ||| S:903 E:904 ||| -RRB-
,  ||| S:904 E:906 ||| ,
docetaxel  ||| S:906 E:916 ||| NN
and  ||| S:916 E:920 ||| CC
mitoxantrone  ||| S:920 E:933 ||| NN
through  ||| S:933 E:941 ||| IN
enhancement  ||| S:941 E:953 ||| NN
of  ||| S:953 E:956 ||| IN
drug-induced  ||| S:956 E:969 ||| JJ
apoptosis  ||| S:969 E:979 ||| NN
but  ||| S:979 E:983 ||| CC
did  ||| S:983 E:987 ||| VBD
not  ||| S:987 E:991 ||| RB
sensitise  ||| S:991 E:1001 ||| JJ
normal  ||| S:1001 E:1008 ||| JJ
cells  ||| S:1008 E:1014 ||| NNS
to  ||| S:1014 E:1017 ||| TO
drugs ||| S:1017 E:1022 ||| NNS
.  ||| S:1022 E:1024 ||| .
The  ||| S:1024 E:1028 ||| DT
double-deleted  ||| S:1028 E:1043 ||| JJ
AdDeltaDelta  ||| S:1043 E:1056 ||| NN
( ||| S:1056 E:1057 ||| -LRB-
DeltaE1ACR2  ||| S:1057 E:1069 ||| NNP
and  ||| S:1069 E:1073 ||| CC
DeltaE1B19K ||| S:1073 E:1084 ||| CD
)  ||| S:1084 E:1086 ||| -RRB-
mutant  ||| S:1086 E:1093 ||| NN
had  ||| S:1093 E:1097 ||| VBD
high  ||| S:1097 E:1102 ||| JJ
cell  ||| S:1102 E:1107 ||| NN
killing  ||| S:1107 E:1115 ||| VBG
activity  ||| S:1115 E:1124 ||| NN
in  ||| S:1124 E:1127 ||| IN
prostate  ||| S:1127 E:1136 ||| NN
and  ||| S:1136 E:1140 ||| CC
pancreatic  ||| S:1140 E:1151 ||| JJ
carcinoma  ||| S:1151 E:1161 ||| JJ
models ||| S:1161 E:1167 ||| NNS
.  ||| S:1167 E:1169 ||| .
Replication  ||| S:1169 E:1181 ||| NNP
was  ||| S:1181 E:1185 ||| VBD
similar  ||| S:1185 E:1193 ||| JJ
to  ||| S:1193 E:1196 ||| TO
the  ||| S:1196 E:1200 ||| DT
parental  ||| S:1200 E:1209 ||| JJ
Ad5  ||| S:1209 E:1213 ||| NN
and  ||| S:1213 E:1217 ||| CC
DeltaCR2  ||| S:1217 E:1226 ||| CD
viruses  ||| S:1226 E:1234 ||| NN
in  ||| S:1234 E:1237 ||| IN
all  ||| S:1237 E:1241 ||| DT
tumour  ||| S:1241 E:1248 ||| JJ
cells  ||| S:1248 E:1254 ||| NNS
and  ||| S:1254 E:1258 ||| CC
was  ||| S:1258 E:1262 ||| VBD
attenuated  ||| S:1262 E:1273 ||| VBN
in  ||| S:1273 E:1276 ||| IN
normal  ||| S:1276 E:1283 ||| JJ
cells ||| S:1283 E:1288 ||| NNS
.  ||| S:1288 E:1290 ||| .
In  ||| S:1290 E:1293 ||| IN
combination  ||| S:1293 E:1305 ||| NN
with  ||| S:1305 E:1310 ||| IN
chemotherapeutics  ||| S:1310 E:1328 ||| JJ
AdDeltaDelta  ||| S:1328 E:1341 ||| JJ
synergistically  ||| S:1341 E:1357 ||| JJ
enhanced  ||| S:1357 E:1366 ||| JJ
cell  ||| S:1366 E:1371 ||| NN
death  ||| S:1371 E:1377 ||| NN
in  ||| S:1377 E:1380 ||| IN
all  ||| S:1380 E:1384 ||| DT
tested  ||| S:1384 E:1391 ||| JJ
cancer  ||| S:1391 E:1398 ||| NN
cell  ||| S:1398 E:1403 ||| NN
lines  ||| S:1403 E:1409 ||| NNS
and  ||| S:1409 E:1413 ||| CC
in  ||| S:1413 E:1416 ||| IN
prostate  ||| S:1416 E:1425 ||| NN
and  ||| S:1425 E:1429 ||| CC
pancreatic  ||| S:1429 E:1440 ||| JJ
xenografts  ||| S:1440 E:1451 ||| NN
in  ||| S:1451 E:1454 ||| IN
vivo ||| S:1454 E:1458 ||| NN
.  ||| S:1458 E:1460 ||| .
These  ||| S:1460 E:1466 ||| DT
data  ||| S:1466 E:1471 ||| NNS
suggest  ||| S:1471 E:1479 ||| VBP
that  ||| S:1479 E:1484 ||| IN
the  ||| S:1484 E:1488 ||| DT
AdDeltaDelta  ||| S:1488 E:1501 ||| JJ
mutant  ||| S:1501 E:1508 ||| NN
is  ||| S:1508 E:1511 ||| VBZ
a  ||| S:1511 E:1513 ||| DT
candidate  ||| S:1513 E:1523 ||| NN
for  ||| S:1523 E:1527 ||| IN
targeting  ||| S:1527 E:1537 ||| VBG
of  ||| S:1537 E:1540 ||| IN
solid  ||| S:1540 E:1546 ||| JJ
tumours  ||| S:1546 E:1554 ||| NNS
specifically  ||| S:1554 E:1567 ||| RB
in  ||| S:1567 E:1570 ||| IN
combination  ||| S:1570 E:1582 ||| NN
with  ||| S:1582 E:1587 ||| IN
cytotoxic  ||| S:1587 E:1597 ||| JJ
factors ||| S:1597 E:1604 ||| NNS
.  ||| S:1604 E:1606 ||| .
Our  ||| S:1606 E:1610 ||| PRP$
findings  ||| S:1610 E:1619 ||| NNS
imply  ||| S:1619 E:1625 ||| VBP
that  ||| S:1625 E:1630 ||| IN
less  ||| S:1630 E:1635 ||| RBR
toxic  ||| S:1635 E:1641 ||| JJ
doses  ||| S:1641 E:1647 ||| NNS
than  ||| S:1647 E:1652 ||| IN
currently  ||| S:1652 E:1662 ||| RB
practised  ||| S:1662 E:1672 ||| VBN
in  ||| S:1672 E:1675 ||| IN
the  ||| S:1675 E:1679 ||| DT
clinic  ||| S:1679 E:1686 ||| NN
could  ||| S:1686 E:1692 ||| MD
efficiently  ||| S:1692 E:1704 ||| RB
target  ||| S:1704 E:1711 ||| VB
adenocarcinomas  ||| S:1711 E:1727 ||| VBN
when  ||| S:1727 E:1732 ||| WRB
combined  ||| S:1732 E:1741 ||| VBN
with  ||| S:1741 E:1746 ||| IN
the  ||| S:1746 E:1750 ||| DT
AdDeltaDelta  ||| S:1750 E:1763 ||| JJ
mutant ||| S:1763 E:1769 ||| NN
.  ||| S:1769 E:1771 ||| .
